RecruitingPhase 2NCT04652115
Defibrotide for the Treatment of Severe COVID-19
A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19
Sponsor
Brigham and Women's Hospital
Enrollment
42 participants
Start Date
Jan 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Defibrotide for people with covid19. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 100 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDefibrotide
Deibrotide via IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04652115
Related Trials
A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx
NCT049914671 location
AGILE (Early Phase Platform Trial for COVID-19)
NCT047461837 locations
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
NCT049564452 locations
Imaging Immune Activation in COVID-19
NCT048150961 location
Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
NCT064821387 locations